Table 2 Multivariable analysis for gene signatures in All, ER + /LN + and ER + /LN− older patients

Genomic grade index

 GG1

453 (52)

1 (−)

–

169 (50)

1 (−)

–

234 (63)

1 (−)

–

 GG3

418 (48)

1.5 (1.1–2)

0.01

166 (50)

1.7 (1.1–2.6)

0.01

140 (37)

1.4 (0.8–2.4)

0.22

70-gene

 Low risk

479 (55)

1 (−)

–

186 (55)

1 (−)

–

249 (67)

1 (−)

–

 High risk

392 (45)

1.7 (1.3–2.3)

 < 0.001

149 (45)

1.6 (1.1–2.5)

0.02

125 (33)

1.9 (1.2–3.3)

0.01

Recurrence score

 Low risk

199 (23)

1 (−)

–

75 (23)

1 (−)

–

106 (28)

1 (−)

–

 Intermediate risk

211 (24)

1.2 (0.8–2)

0.41

98 (29)

1.2 (0.7–2.3)

0.51

102 (27)

1.2 (0.6–2.6)

0.62

 High risk

461 (53)

2 (1.3–3.1)

0.001

162 (48)

2.4 (1.4–4.3)

0.002

166 (45)

1.6 (0.8—3.1)

0.21

Cell cycle score

 Low

329 (38)

1 (−)

118 (35)

1 (−)

–

166 (44)

1 (−)

–

 Intermediate

283 (32)

1.7 (1.2–2.5)

0.005

128 (38)

1.7 (1–2.8)

0.04

130 (35)

2 (1–3.7)

0.04

 High

259 (30)

2.3 (1.5–3.5)

 < 0.001

89 (27)

2.7 (1.6–4.7)

 < 0.001

78 (21)

2.2 (1.1–4.4)

0.02

ROR-P

 Low proliferation

206 (24)

1 (−)

–

69 (21)

1 (−)

–

118 (32)

1 (−)

–

 Int. proliferation

532 (61)

1.7 (1.1–2.6)

0.03

236 (70)

2.3 (1.2 – 4.5)

0.01

221 (59)

1.2 (0.7–2.3)

0.49

 High proliferation

133 (15)

3.2 (1.8–5.6)

 < 0.001

30 (9)

5.6 (2.4–13.2)

 < 0.001

35 (9)

2.7 (1.2–6.4)

0.02

PAM50

 Luminal A

493 (57)

1 (−)

–

204 (61)

1 (−)

–

251 (67)

1 (−)

–

 Luminal B

206 (24)

1.5 (1.1–2.1)

0.02

94 (28)

1.3 (0.8–2)

0.26

88 (24)

1.9 (1.1–3.3)

0.02

 Her2-enriched

69 (8)

1.6 (0.9–2.8)

0.1

23 (7)

1.4 (0.7–2.9)

0.34

11 (3)

2.1 (0.6–7.2)

0.23

 Basal-like

65 (7)

0.8 (0.3–2)

0.65

5 (1)

2.4 (0.6–10)

0.23

5 (1)

0.9 (0.1–6.7)

0.92

 Normal-like

38 (4)

0.7 (0.3–1.7)

0.39

9 (3)

0.5 (0.1–2.1)

0.36

19 (5)

0.4 (0.1–2.7)

0.32